ArticleEye (London, England)2026
Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS).
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Historical controls and modelled costs cannot support first-line amniotic membrane for persistent epithelial defects.Eye (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate clinical outcomes and resource utilisation of conventional treatment modalities for ocular surface disease involving inflammation and persistent epithelial defect (PED) in an NHS setting, and to compare outcomes with sutureless human amniotic membrane-derived dry matrix (HAMDM) as an alternative therapy.
methodsA retrospective clinical study of 30 patients with PED was conducted across two centres. Treatment duration, healing rates, outpatient (OP) burden, and associated costs were analysed. Outcomes were benchmarked against pooled data from prior studies with HAMDM at the same centres.
resultsConventional management achieved complete healing in 57% of patients, with a mean treatment duration of 176 ± 188 days and 10 OP visits per case. Adjunctive procedures such as tarsorrhaphy (83%) and amniotic membrane transplantation (AMT, 34%) were frequently required. The average total cost per patient was £ 4900 ± £ 3363. In comparison, patients treated with HAMDM achieved higher resolution rates (63%), shorter treatment duration (98 days), fewer OP appointments (8 per case), and a lower treatment cost.
conclusionPED poses a substantial clinical and economic burden within the NHS. Standard treatments are prolonged and resource-intensive. HAMDM represents a clinically effective and cost-saving alternative, potentially reducing treatment duration, OP burden and overall healthcare costs. Hospital Episode Statistics (HES) data revealed over 138,000 PED-related episodes annually in the NHS, primarily managed in non-surgical settings. These findings therefore support further integration of sutureless amniotic membrane into first-line care strategies for ocular surface disease involving inflammation and PED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.